GO:0035771 interleukin-4-mediated signaling pathway: Immune Regulation Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0035771 describes the molecular cascade triggered when interleukin-4 (IL-4) binds its receptor, culminating in transcriptional regulation.
• The pathway critically depends on JAK-mediated phosphorylation and activation of STAT6, which translocates to the nucleus to control gene expression.
• IL-4 signaling regulates B-cell proliferation, differentiation, survival, and immunoglobulin class switching, and it suppresses macrophage inflammatory functions.
• Negative regulators such as protein phosphatase 2A (PP2A) and naturally occurring dominant-negative STAT6 variants modulate pathway intensity.
• Pathway dysregulation is implicated in allergic inflammation, B-cell malignancies, and viral latency, making it a target for therapeutic intervention.
• CRISPR-based knockout, point-mutation, knock-in, and overexpression models enable precise dissection of IL-4 signaling components in immune cells.
Description
Interleukin-4 (IL-4) is a pleiotropic cytokine that orchestrates immune responses by binding to its cell-surface receptor and initiating a signaling cascade defined by the Gene Ontology term GO:0035771, interleukin-4-mediated signaling pathway. This pathway converts extracellular IL-4 binding into changes in gene transcription, thereby controlling cell proliferation, survival, differentiation, and effector functions in lymphocytes and myeloid cells. Researchers study GO:0035771 to understand how immune cells interpret IL-4 signals and how disruptions contribute to disease. The pathway is best known for activating the transcription factor STAT6 through Janus kinase (JAK)-mediated tyrosine phosphorylation. Once phosphorylated, STAT6 dimerizes, translocates to the nucleus, and regulates target genes such as BCL2L1 (encoding Bcl-xL), which promotes B-cell survival. Beyond STAT6, additional regulators including protein phosphatase 2A (PP2A) and SH2-containing inositol-5'-phosphatase (SHIP) fine-tune the strength and duration of IL-4 signaling. Because IL-4 signaling influences both protective immunity and pathological inflammation, it is a focal point for studies in allergy, autoimmunity, cancer, and infectious disease. Understanding GO:0035771 at molecular resolution requires integrating receptor-proximal events, kinase/phosphatase dynamics, and transcriptional outputs, which can be systematically interrogated using CRISPR-based genome editing and functional genomics.
interleukin-4-mediated signaling pathway At A Glance
| GO ID | GO:0035771 |
|---|---|
| GO term | interleukin-4-mediated signaling pathway |
| Ontology | biological_process |
| Synonym | IL-4-mediated signaling pathway; interleukin-4-mediated signalling pathway |
| Major function | Transduces IL-4 receptor engagement into transcriptional and cellular responses, including proliferation, survival, and differentiation |
| Key effector | STAT6, activated by JAK-mediated phosphorylation |
| Negative regulators | Protein phosphatase 2A (PP2A) and dominant-negative STAT6 variants |
| Cellular contexts | B cells, T cells, macrophages, and other IL-4-responsive cells |
| Disease relevance | Allergic inflammation, B-cell malignancies, viral latency, and macrophage-mediated immunity |
What Is GO:0035771?
GO:0035771, interleukin-4-mediated signaling pathway, is defined as the series of molecular signals initiated by interleukin-4 binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription. In practice, this term encompasses receptor engagement, activation of associated kinases, phosphorylation and activation of downstream effectors such as STAT6, and the resulting changes in gene expression that alter cell behavior.
Why Is interleukin-4-mediated signaling pathway Important in Cell Biology?
GO:0035771 is essential for understanding how a single cytokine can reprogram immune cell fate and function. IL-4 signaling drives B-cell proliferation and survival, promotes immunoglobulin class switching, and suppresses pro-inflammatory macrophage activities, thereby shaping both humoral immunity and tissue inflammation. Because the pathway is frequently co-opted in disease, including B-cell lymphomas and virus-associated malignancies, it represents a tractable target for therapeutic modulation. Moreover, the pathway serves as a paradigm for cytokine receptor signaling, linking extracellular cues to STAT6-dependent transcription and providing a framework for studying kinase/phosphatase balance in immune regulation.
• Controls B-cell proliferation and differentiation, including immunoglobulin class switching.
• Promotes B-cell survival through STAT6-dependent upregulation of Bcl-xL.
• Suppresses nitric oxide production in macrophages, modulating inflammatory responses.
• Regulates apoptosis and latency in virus-infected cells, as shown for Kaposi's sarcoma-associated herpesvirus.
• Is fine-tuned by PP2A, which dephosphorylates and inactivates STAT6.
• Naturally occurring dominant-negative STAT6 variants attenuate IL-4 signaling, highlighting regulatory mechanisms.
• SHIP positively regulates IL-4-mediated proliferation, revealing additional layers of control.
• Dysregulation is linked to allergic diseases, autoimmunity, and B-cell malignancies.
• Provides a model for JAK-STAT signaling that is broadly relevant to cytokine biology.
• Offers targets for CRISPR-based functional studies in immune cells.
What Happens During interleukin-4-mediated signaling pathway?
IL-4 binding and receptor activation
In simple terms: IL-4 docks onto its receptor on the cell surface, switching it on.
The pathway begins when interleukin-4 binds to its receptor complex on the surface of a target cell, triggering receptor activation and the initiation of intracellular signaling. This binding event is the defining trigger for GO:0035771 and sets in motion a cascade that ultimately regulates transcription.
JAK-mediated phosphorylation and STAT6 activation
In simple terms: Enzymes called JAKs add phosphate groups to STAT6, turning it on.
Following receptor engagement, Janus kinases (JAKs) phosphorylate the transcription factor STAT6 on specific tyrosine residues, causing STAT6 to dimerize and become transcriptionally active. This step is a central node in the pathway, and its disruption by dominant-negative STAT6 variants blocks IL-4-mediated biological functions.
STAT6 nuclear translocation and target gene regulation
In simple terms: Activated STAT6 moves into the nucleus and turns genes on or off.
Phosphorylated STAT6 dimers translocate to the nucleus, where they bind DNA and regulate target genes that control cell proliferation, survival, and differentiation. A well-characterized example is the upregulation of Bcl-xL, which protects primary B cells from apoptosis in a STAT6-dependent manner.
Negative regulation by phosphatases and dominant-negative variants
In simple terms: Brakes exist to stop the signal, including enzymes that remove phosphates.
Protein phosphatase 2A (PP2A) regulates IL-4-mediated STAT6 signaling by dephosphorylating STAT6, thereby attenuating the pathway. In addition, naturally occurring dominant-negative and attenuated forms of human STAT6 can suppress IL-4-mediated signaling, providing intrinsic control mechanisms.
Modulation by SHIP and other regulators
In simple terms: Other molecules can boost or shape the signal.
The SH2-containing inositol-5'-phosphatase (SHIP) positively regulates IL-4-mediated proliferation, indicating that the pathway is subject to additional layers of control beyond STAT6. These regulatory inputs ensure that IL-4 responses are context-dependent and tightly controlled.
Downstream cellular outcomes
In simple terms: The signal changes how the cell behaves, such as surviving or multiplying.
The ultimate outputs of GO:0035771 include altered proliferation, differentiation, survival, and effector functions. For example, IL-4 signaling inhibits nitric oxide production in macrophages, modulates B-cell proliferation and differentiation, and can influence viral latency and apoptosis in infected cells.
Key Genes Involved in GO:0035771 interleukin-4-mediated signaling pathway
The following genes and proteins are central to the interleukin-4-mediated signaling pathway (GO:0035771) and are frequently studied using CRISPR-based approaches.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IL4 | Ligand that initiates the pathway by binding its receptor | Target for overexpression or knockout to study pathway activation |
| IL4R | Receptor subunit that binds IL-4 and activates JAKs | Knockout to abolish IL-4 signaling; point mutations to map binding sites |
| JAK1 | Kinase that phosphorylates STAT6 upon receptor activation | Knockout or kinase-dead knock-in to block STAT6 activation |
| JAK3 | Kinase that cooperates with JAK1 in IL-4 receptor signaling | Knockout to dissect kinase redundancy |
| STAT6 | Transcription factor activated by phosphorylation; key effector | Knockout, dominant-negative knock-in, or tagged knock-in for localization studies |
| PP2A | Phosphatase that dephosphorylates STAT6 and attenuates signaling | Overexpression or knockout to modulate pathway strength |
| SHIP | Positively regulates IL-4-mediated proliferation | Knockout to assess its role in proliferation |
| BCL2L1 | Encodes Bcl-xL; upregulated by STAT6 to promote survival | Overexpression or knockout to study apoptosis |
| CD45R (B220) | Epitope whose targeting inhibits IL-4-mediated B cell responses | Antibody-based or knockout models to study B cell proliferation |
| NOS2 | Nitric oxide synthase; inhibited by IL-4 signaling | Knockout to study macrophage inflammatory output |
| KSHV ORF | Viral factors that inhibit STAT6 phosphorylation | Infection models to study viral latency |
| SOCS1 | Potential negative regulator of cytokine signaling (implied by pathway context) | Knockout to test pathway enhancement |
| SOCS3 | Potential negative regulator of cytokine signaling (implied by pathway context) | Knockout to test pathway enhancement |
| PI3K | Lipid kinase potentially downstream of SHIP | Knockout or inhibitor studies to map proliferation signals |
| NF-κB | Transcription factor cross-talk with IL-4 signaling (implied by inflammatory regulation) | Reporter assays and knockout to study crosstalk |
| Bcl-xL | Anti-apoptotic protein upregulated by STAT6 | Overexpression to rescue apoptosis in STAT6-null cells |
| IL-4Rα | Alternative name for IL4R subunit | Knock-in of tagged receptor for imaging |
| STAT6 dominant-negative | Naturally occurring variant that blocks signaling | Knock-in to create signaling-deficient cells |
How Is interleukin-4-mediated signaling pathway Regulated?
The interleukin-4-mediated signaling pathway is regulated at multiple levels. Protein phosphatase 2A (PP2A) directly dephosphorylates STAT6, thereby terminating or dampening the signal. Naturally occurring dominant-negative and attenuated forms of human STAT6 can interfere with pathway activation, acting as intrinsic brakes. Additionally, SHIP positively regulates IL-4-mediated proliferation, suggesting that lipid phosphatase activity contributes to pathway output. These regulatory mechanisms ensure that IL-4 responses are appropriately scaled and transient, preventing excessive immune activation.
interleukin-4-mediated signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| STAT6 | Allergic asthma, B-cell lymphoma survival | STAT6 knockout or dominant-negative knock-in in B cells |
| IL4 | Atopic dermatitis, asthma | IL4 overexpression or knockout in mouse models |
| IL4R | Allergic inflammation, immunodeficiency | IL4R knockout or point-mutation knock-in |
| BCL2L1 | B-cell lymphoma apoptosis resistance | Bcl-xL overexpression or knockout in lymphoma lines |
| KSHV factors | Viral latency and pathogenesis | KSHV infection of CRISPR-edited cells |
Allergic inflammation and asthma
IL-4 signaling is a central driver of Th2-type immune responses, and its dysregulation contributes to allergic inflammation. The pathway promotes B-cell class switching to IgE and modulates macrophage function, both of which are implicated in asthma and atopic diseases. Targeting STAT6 or upstream kinases is a therapeutic strategy under investigation.
B-cell malignancies
IL-4-mediated protection of primary B cells from apoptosis through STAT6-dependent upregulation of Bcl-xL suggests that this pathway can promote survival of malignant B cells. Consequently, inhibitors of IL-4 signaling or STAT6 are being explored to sensitize B-cell lymphomas to apoptosis.
Viral latency and pathogenesis
Kaposi's sarcoma-associated herpesvirus (KSHV) inhibits IL-4-mediated STAT6 phosphorylation to regulate apoptosis and maintain latency, indicating that the pathway is a target for viral immune evasion. This highlights the importance of GO:0035771 in host-pathogen interactions.
Macrophage-mediated immunity
IL-4 signaling inhibits nitric oxide production in interferon-gamma-treated and virus-infected macrophages, thereby shaping inflammatory responses. Dysregulation of this axis may contribute to chronic inflammatory diseases.
From interleukin-4-mediated signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does STAT6 mediate IL-4-induced B-cell survival? | STAT6 knockout B cells |
| What is the role of PP2A in STAT6 dephosphorylation? | PP2A overexpression or knockout |
| Can dominant-negative STAT6 block IL-4 signaling? | Knock-in of dominant-negative STAT6 |
| How does SHIP regulate IL-4-mediated proliferation? | SHIP knockout or overexpression |
| Does IL-4 signaling inhibit macrophage NO production? | IL4R knockout macrophages |
| How does KSHV inhibit STAT6 phosphorylation? | KSHV infection with STAT6 reporters |
How to Study the interleukin-4-mediated signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Phospho-STAT6 immunoblot | STAT6 activation | Testing pathway inhibitors or CRISPR edits |
| STAT6 luciferase reporter | Transcriptional activity | Screening regulators |
| Proliferation assay | Cell division | Assessing IL-4-mediated proliferation |
| Apoptosis assay | Cell survival | Evaluating Bcl-xL upregulation |
| Griess assay | Nitric oxide production | Macrophage functional studies |
| Flow cytometry | Surface markers and phospho-proteins | B-cell differentiation and STAT6 phosphorylation |
| qRT-PCR | Target gene expression | Measuring Bcl-xL or other STAT6 targets |
| CRISPR screening | Gene essentiality in pathway | Identifying novel regulators |
Phospho-STAT6 immunoblotting and flow cytometry
Measuring phosphorylated STAT6 by immunoblotting or flow cytometry is a direct way to assess pathway activation after IL-4 stimulation. This method is widely used to test the impact of CRISPR edits in JAKs or STAT6.
Transcriptional reporter assays
STAT6-responsive luciferase reporters can quantify pathway output and are useful for screening regulators such as PP2A or SHIP. These assays are compatible with high-throughput formats.
Proliferation and apoptosis assays
IL-4-mediated proliferation and protection from apoptosis can be measured using thymidine incorporation, CFSE dilution, or Annexin V staining. These functional readouts link pathway activity to cellular outcomes.
Nitric oxide production measurement
In macrophages, IL-4-mediated inhibition of nitric oxide production can be quantified using Griess reagent, providing a functional readout of pathway activity.
How CRISPR Can Be Used to Study GO:0035771 interleukin-4-mediated signaling pathway
Knockout
CRISPR knockout of STAT6, JAK1, or IL4R can abolish IL-4-mediated signaling, providing definitive loss-of-function models to test pathway necessity. Such models are valuable for validating drug targets and understanding disease mechanisms.
Point Mutation
Introducing point mutations in STAT6 phosphorylation sites or in the IL-4 receptor binding interface can dissect specific molecular interactions without eliminating protein expression. This approach is useful for studying dominant-negative variants.
Knock-in
Knock-in of tagged STAT6 or IL4R allows real-time imaging and biochemical purification of pathway components. Knock-in of dominant-negative STAT6 can create signaling-deficient cells for comparison.
Overexpression
Overexpression of PP2A or SHIP can enhance negative regulation or positive regulation of the pathway, respectively, enabling gain-of-function studies. Overexpression of Bcl-xL can rescue apoptosis in STAT6-null cells.
How EDITGENE Supports interleukin-4-mediated signaling pathway Research
Researchers studying interleukin-4-mediated signaling pathway-related genes often need to determine whether a candidate gene is causally involved in pathway activation, regulation, or downstream outcomes. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for interleukin-4-mediated signaling pathway research.
Frequently Asked Questions About interleukin-4-mediated signaling pathway
What is GO:0035771?
GO:0035771 is the Gene Ontology term for the interleukin-4-mediated signaling pathway, defined as the series of molecular signals initiated by IL-4 binding to its receptor and ending with regulation of a downstream cellular process such as transcription.
What genes are involved in interleukin-4-mediated signaling pathway?
Key genes include IL4, IL4R, JAK1, JAK3, STAT6, PP2A, SHIP, and BCL2L1, among others.
How does IL-4 activate STAT6?
IL-4 binding activates JAK kinases, which phosphorylate STAT6, causing it to dimerize, enter the nucleus, and regulate target genes.
What is the role of STAT6 in IL-4 signaling?
STAT6 is the principal transcription factor downstream of IL-4 receptor activation and is required for many IL-4-mediated biological functions, including B-cell survival and differentiation.
How is IL-4 signaling negatively regulated?
Protein phosphatase 2A (PP2A) dephosphorylates STAT6 to attenuate signaling, and dominant-negative STAT6 variants can block pathway activation.
What diseases are associated with IL-4 signaling?
Dysregulated IL-4 signaling is linked to allergic inflammation, asthma, B-cell malignancies, and viral latency.
Can CRISPR be used to study IL-4 signaling?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are powerful tools to dissect the pathway and identify therapeutic targets.
What is the role of SHIP in IL-4 signaling?
SHIP positively regulates IL-4-mediated proliferation, indicating it contributes to pathway output.
How does KSHV affect IL-4 signaling?
Kaposi's sarcoma-associated herpesvirus inhibits IL-4-mediated STAT6 phosphorylation to regulate apoptosis and maintain latency.
What experimental models are used to study IL-4 signaling?
Common models include STAT6 knockout B cells, PP2A overexpression, and reporter assays for transcriptional activity.
Conclusion
GO:0035771, the interleukin-4-mediated signaling pathway, is a central mechanism by which IL-4 shapes immune cell behavior, from B-cell survival to macrophage suppression. Its core components, including JAK kinases, STAT6, PP2A, and SHIP, are well-characterized and serve as attractive targets for therapeutic intervention in allergy, cancer, and infectious disease. CRISPR-based genome editing offers a precise approach to model pathway perturbations and uncover new regulatory nodes, accelerating both basic discovery and translational research.
References
- 1. Woetmann A et al.. 2003. Protein phosphatase 2A (PP2A) regulates interleukin-4-mediated STAT6 signaling.. J Biol Chem 278(5):2787-91 PMID: 12426308
- 2. Patel BK et al.. 1998. Regulation of interleukin 4-mediated signaling by naturally occurring dominant negative and attenuated forms of human Stat6.. Proc Natl Acad Sci U S A 95(1):172-7 PMID: 9419348
- 3. Takeda K et al.. 1997. STAT6: its role in interleukin 4-mediated biological functions.. J Mol Med (Berl) 75(5):317-26 PMID: 9181473
- 4. Paludan SR et al.. 1999. Interleukin-4-mediated inhibition of nitric oxide production in interferon-gamma-treated and virus-infected macrophages.. Scand J Immunol 49(2):169-76 PMID: 10075021
- 5. Giallourakis C et al.. 2000. Positive regulation of interleukin-4-mediated proliferation by the SH2-containing inositol-5'-phosphatase.. J Biol Chem 275(38):29275-82 PMID: 10875931
- 6. Wurster AL et al.. 2002. Interleukin-4-mediated protection of primary B cells from apoptosis through Stat6-dependent up-regulation of Bcl-xL.. J Biol Chem 277(30):27169-75 PMID: 12023955
- 7. Cai Q et al.. 2010. Kaposi's sarcoma-associated herpesvirus inhibits interleukin-4-mediated STAT6 phosphorylation to regulate apoptosis and maintain latency.. J Virol 84(21):11134-44 PMID: 20719954
- 8. Hasegawa K et al.. 1990. Monoclonal antibodies to epitope of CD45R (B220) inhibit interleukin 4-mediated B cell proliferation and differentiation.. Int Immunol 2(4):367-75 PMID: 1703782
